MX2018014576A - Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos. - Google Patents
Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.Info
- Publication number
- MX2018014576A MX2018014576A MX2018014576A MX2018014576A MX2018014576A MX 2018014576 A MX2018014576 A MX 2018014576A MX 2018014576 A MX2018014576 A MX 2018014576A MX 2018014576 A MX2018014576 A MX 2018014576A MX 2018014576 A MX2018014576 A MX 2018014576A
- Authority
- MX
- Mexico
- Prior art keywords
- nanoparticles
- segment
- oligonucleotide
- double
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342829P | 2016-05-27 | 2016-05-27 | |
| PCT/US2017/034719 WO2017205764A1 (en) | 2016-05-27 | 2017-05-26 | Drug-delivery nanoparticles and treatments for drug-resistant cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014576A true MX2018014576A (es) | 2019-06-06 |
Family
ID=60411649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014576A MX2018014576A (es) | 2016-05-27 | 2017-05-26 | Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190175747A1 (enExample) |
| EP (1) | EP3463468A4 (enExample) |
| JP (1) | JP2019517477A (enExample) |
| KR (1) | KR20190013929A (enExample) |
| CN (1) | CN109475636A (enExample) |
| AU (1) | AU2017271662A1 (enExample) |
| BR (1) | BR112018074304A2 (enExample) |
| CA (1) | CA3025348A1 (enExample) |
| EA (1) | EA201892797A1 (enExample) |
| IL (1) | IL263227A (enExample) |
| MX (1) | MX2018014576A (enExample) |
| SG (1) | SG11201810403VA (enExample) |
| WO (1) | WO2017205764A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CN104619839A (zh) * | 2012-08-03 | 2015-05-13 | 西塞医疗中心 | 药物递送蛋白质的增强运输的突变体的分离 |
| RU2674146C2 (ru) | 2013-05-08 | 2018-12-07 | Седарс-Синай Медикал Центр | Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт |
| RU2682335C2 (ru) | 2014-01-17 | 2019-03-19 | Сидарс-Синай Медикал Сентр | Рецептор-направленные конструкции и их применение |
| WO2018067526A1 (en) * | 2016-10-03 | 2018-04-12 | Eos Biosciences, Inc. | Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles |
| WO2019136005A1 (en) * | 2018-01-02 | 2019-07-11 | Cedars-Sinai Medical Center | Nanoparticles for the targeted delivery of therapeutic polypeptides |
| CN119015258A (zh) * | 2019-09-06 | 2024-11-26 | 加利福尼亚大学董事会 | 核酸介导的治疗剂的递送 |
| CN115282283B (zh) * | 2022-06-21 | 2024-11-29 | 上海交通大学 | 一种小分子药物-寡核苷酸偶联物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US9078927B2 (en) * | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2010085665A2 (en) * | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CA2772660A1 (en) * | 2009-09-01 | 2011-03-10 | Northwestern University | Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers |
| MX2016013025A (es) * | 2014-04-04 | 2017-04-27 | Cedars Sinai Medical Center | Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3. |
| WO2016032595A1 (en) * | 2014-08-27 | 2016-03-03 | Peptimed, Inc. | Anti-tumor compositions and methods |
-
2017
- 2017-05-26 MX MX2018014576A patent/MX2018014576A/es unknown
- 2017-05-26 WO PCT/US2017/034719 patent/WO2017205764A1/en not_active Ceased
- 2017-05-26 US US16/304,501 patent/US20190175747A1/en not_active Abandoned
- 2017-05-26 AU AU2017271662A patent/AU2017271662A1/en not_active Abandoned
- 2017-05-26 BR BR112018074304A patent/BR112018074304A2/pt not_active Application Discontinuation
- 2017-05-26 KR KR1020187037729A patent/KR20190013929A/ko not_active Ceased
- 2017-05-26 CA CA3025348A patent/CA3025348A1/en not_active Abandoned
- 2017-05-26 EA EA201892797A patent/EA201892797A1/ru unknown
- 2017-05-26 JP JP2018562097A patent/JP2019517477A/ja active Pending
- 2017-05-26 CN CN201780043181.8A patent/CN109475636A/zh active Pending
- 2017-05-26 SG SG11201810403VA patent/SG11201810403VA/en unknown
- 2017-05-26 EP EP17803677.8A patent/EP3463468A4/en not_active Withdrawn
-
2018
- 2018-11-22 IL IL263227A patent/IL263227A/en unknown
-
2025
- 2025-01-10 US US19/017,303 patent/US20250255978A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475636A (zh) | 2019-03-15 |
| US20190175747A1 (en) | 2019-06-13 |
| EP3463468A4 (en) | 2020-11-11 |
| SG11201810403VA (en) | 2018-12-28 |
| EP3463468A1 (en) | 2019-04-10 |
| JP2019517477A (ja) | 2019-06-24 |
| US20250255978A1 (en) | 2025-08-14 |
| BR112018074304A2 (pt) | 2019-10-01 |
| WO2017205764A1 (en) | 2017-11-30 |
| IL263227A (en) | 2018-12-31 |
| EA201892797A1 (ru) | 2019-06-28 |
| KR20190013929A (ko) | 2019-02-11 |
| AU2017271662A1 (en) | 2018-12-06 |
| CA3025348A1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018014576A (es) | Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos. | |
| CO2020003478A2 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| MX2019005736A (es) | Composicion farmaceutica para prevenir o tratar el cancer de mama que incluye polimorfo cristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. | |
| EP4501352A3 (en) | Compositions and methods for car t cell therapy | |
| MX392459B (es) | Composicion farmaceutica para la prevencion o tratamiento de cancer, que comprende polimorfo cristalino de hexoxido de tetraarsenico | |
| MX2019005737A (es) | Composicion farmaceutica para prevenir o tratar el cancer de cerebro que incluye polimorfocristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. | |
| CR20150616A (es) | Composiciones y métodos para activar la señalización que depende del "estimulador del gen de interferón" | |
| CO7160093A2 (es) | Anticuerpos anti-egfr y usos de los mismos | |
| MX389700B (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2018012391A (es) | Administracion intratumoral de particulas que contengan un agonista del receptor 9 tipo toll y un antigeno tumoral para el tratamiento contra el cancer. | |
| AR100560A1 (es) | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido | |
| CO2017013432A2 (es) | Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones | |
| MX2017006942A (es) | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. | |
| CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| UY36579A (es) | Composiciones y métodos para activar la señalización dependiente del “estimulador del gen interferon. | |
| MX2016013027A (es) | Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario. | |
| AR091220A1 (es) | Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf | |
| CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
| AR088171A1 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
| MX2017000578A (es) | Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. | |
| PE20160591A1 (es) | Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma) | |
| ECSP17014159A (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| MX2021005395A (es) | Terapia del cáncer con células inmunitarias anti-liv1. | |
| MX2021005400A (es) | Terapia del cancer con celulas inmunitarias anti-ptk7. |